Abbvie

N61AV

2024 GULFSTREAM AEROSPACE CORP GVII-G600

AbbVie Inc. (NYSE: ABBV) stands as a global research-driven biopharmaceutical leader, dedicated to developing innovative medicines for today’s most serious health challenges. Renowned for its dominance in immunology with the blockbuster drug Humira and its successors Skyrizi and Rinvoq, the company has successfully expanded its portfolio to include cutting-edge treatments in oncology, neuroscience, and eye care. Following the acquisition of Allergan, AbbVie is also the powerhouse behind Botox and a premier portfolio of medical aesthetics. Headquartered in North Chicago, Illinois, and recognized as a reliable Dividend King, AbbVie combines advanced science with patient-centric care to drive the future of medicine.